|
Pneumonia
|
0.310 |
Biomarker
|
disease |
BEFREE |
Murine models indicate key roles for chemokines CCL19 and CCL21 and their receptor CCR7 in lung inflammation leading to PAH.
|
29687634 |
2018 |
|
Pneumonitis
|
0.310 |
Biomarker
|
disease |
BEFREE |
Murine models indicate key roles for chemokines CCL19 and CCL21 and their receptor CCR7 in lung inflammation leading to PAH.
|
29687634 |
2018 |
|
Pneumonia
|
0.310 |
Biomarker
|
disease |
CTD_human |
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression.
|
21625544 |
2011 |
|
Pneumonitis
|
0.310 |
Biomarker
|
disease |
CTD_human |
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression.
|
21625544 |
2011 |
|
Dermatitis, Allergic Contact
|
0.310 |
Biomarker
|
disease |
CTD_human |
Gene expression time course in the human skin during elicitation of allergic contact dermatitis.
|
17597826 |
2007 |
|
Dermatitis, Allergic Contact
|
0.310 |
AlteredExpression
|
disease |
LHGDN |
Gene expression time course in the human skin during elicitation of allergic contact dermatitis.
|
17597826 |
2007 |
|
Hypersensitivity
|
0.300 |
Biomarker
|
group |
CTD_human |
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression.
|
21625544 |
2011 |
|
Lobar Pneumonia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression.
|
21625544 |
2011 |
|
Experimental Lung Inflammation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression.
|
21625544 |
2011 |
|
Allergic Reaction
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORγt cells in allergic inflammation, local lung distribution and chemokine gene expression.
|
21625544 |
2011 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CCL19, a ligand of CCR7, could promote trophoblast migration and invasion by activating the deregulation of the CCR7-mediated pathway in RSA.
|
31504210 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.
|
31526758 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eight markers were statistically significantly higher with tumor EBV positivity: chemokine C-C motif ligand (CCL) 20 (Odds Ratio (OR) = 3.6; <i>p</i>-trend = 0.001), chemokine C-X-C motif ligand 9 (OR = 3.6; <i>p</i>-trend = 0.003), programmed death-ligand 1 (PD-L1; OR = 3.4; <i>p</i>-trend = 0.004), interleukin (IL)-10 (OR = 2.4; <i>p</i>-trend = 0.019), CCL19 (OR = 2.3; <i>p</i>-trend = 0.019), CCL11 (OR = 2.2; <i>p</i>-trend = 0.026), IL-17A (OR = 2.0; <i>p</i>-trend = 0.038) and CCL8 (OR = 1.9; <i>p</i>-trend = 0.049).
|
30142953 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeted ablation of CCL19-expressing tumor FSCs reduced immune cell recruitment and resulted in unleashed tumor growth.
|
29391257 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.
|
29505028 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Further, enhanced expression of CCR5 and CCR7 on T<sub>regs</sub> with up regulation of their ligands (CCL5, CCL19, and CCL21) in tumor cells indicates efficient recruitment and trafficking of T<sub>regs</sub> to the tumor site.
|
28833201 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The results demonstrated that CCL19 mediated cell invasion and migration by inducing the EMT, with downregulation of E-cadherin and up-regulation of N-cadherin and vimentin levels.
|
28378417 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Migration and invasion assays and immunofluorescence staining experiments demonstrated that CCL19 promoted cell migration, invasion and F-actin rearrangment in CCR7-expressing SCCHN cells partially due to the activation of the Jak3 signaling pathway.
|
28521425 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Further analyses showed that inhibitory effects of CCL19 on cell migration and invasion were partly associated with EMT process.
|
29088748 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Silencing of CCL19 inhibited the proliferation of DU-145 cells which have a relatively high level of CCL19 in a time- and concentration-dependent manner, and the invasion and migration of DU-145 cells were distinctly suppressed.
|
25256673 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, these findings demonstrate that EMT can be regulated by the CCL19/CXCR7 axis in epithelial ovarian carcinomas and then involved in the tumor cell invasion and metastasis process via activation of AKT and ERK pathways.
|
25359618 |
2015 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In vitro, the roles of CrkL in CCL19-stimulated SKOV-3 cell invasion and migration were investigated.
|
25636509 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The CCL19 expression correlated with tumor size (P = 0.03) and invasion depth (P = 0.04) in a negative manner and CCL19-positive patients had longer lifespans (P < 0.05).
|
24705643 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, RNAi-mediated change of HERV-H or CCL19, or depletion of CD271(+) cells, improved immune responses in vitro and in vivo accompanied by tumor regression.
|
24590808 |
2014 |